To evaluate the efficacy of NF-κB-CEA enhancer–promoter system in 5′-DFUR prodrug based GDEPT, it is essential to determine the background status of TP (protein and enzyme activity), CEA (mRNA and protein) and NF-κB (transcriptional activity) in cancer and normal cells. The gene discussed is NFKB1; the disease is cancer.